The time to re-enter the RNAi revolution is now,” said Robert Nelsen, the managing director of Arch, which led the Series A funding round for City Therapeutics.
The Cambridge, Massachusetts-based biotech is using what it calls ligand-siRNA conjugates to reach drug targets in the kidney, which historically have been difficult to reach with RNA therapies.
Gene-silencing specialist Alnylam has completed filings in the US and EU for lumasiran, which aced a phase 3 trial in kidney disorder primary hyperoxaluria type 1 (PH1) last year. Lumasiran is the ...
Two exchange-traded funds known as the XBI and IBB that track biotech industry indices followed a similar pattern. The cut “will be very positive for the biotech capital markets,” said John Maraganore ...